Bnf

Chapter 5 ~ Infections: Special Section 1 of 5 Chapter 5 ~ Infections
Please refer to The Hillingdon Hospitals NHS Trust Antibiotic Guidelines, Policy number 233,
and Surgical Prophylaxis Policy, Policy number 234
Notifiable diseases
Doctors must notify the consultant in communicable disease control when attending a patient suspected of
suffering from any of the diseases listed below:
5.1 Antibacterial drugs
5.1.1 Penicillins
5.1.1.2 Penicillinase-resistant penicillins
TEMOCILLIN

Injection 1g
 Non Policy Antibiotic  Requires Microbiology Approval 5.1.1.3 Broad-spectrum penicillins
AMOXICILLIN

PowderSF 3 g
CO-AMOXICLAV
SuspensionSF 400/57 in
5.1.1.4 Antipseudomonal penicillins
PIPERACILLIN with

Injection 2g/250mg;
tazobactam (TAZOCIN®) 4g/500mg
TICARCILLIN with
Injection 3g/200mg
clavulanic acid
(TIMENTIN®)

5.1.2 Cephalosporins and other beta-lactams
CEFIXIME

Suspension 100mg in
Tablet 200 mg
CEFTAZIDIME
Injection 500mg; 1g; 2g
CEFTRIAXONE
Injection 250mg; 1g
CEFUROXIME
Injection 250mg; 1.5g
ERTAPENEM
Intravenous infusion
IMIPENEM with
Intravenous infusion
Cilastatin
MEROPENEM
Injection 500mg; 1g
5.1.3 Tetracyclines
LYMECYCLINE

Capsule 408mg (=
MINOCYCLINE
Modified release
Chapter 5 ~ Infections: Special Section 2 of 5 capsule 100mg
Tablet 50mg;
OXYTETRACYCLINE
Tablet 250mg
5.1.3 Tetracyclines (contd.)
TIGECYCLINE

Intravenous infusion
5.1.4 Aminoglycosides
AMIKACIN

Injection 500mg in 2ml
GENTAMICIN
Intrathecal injection
TOBRAMYCIN
Injection 40mg in 1ml;
5.1.5 Macrolides
AZITHROMYCIN

Capsule 250mg
 For Obstetrics and Gynaecology  For Genito Urinary Medicine Suspension 200mg in
5.1.6 Clindamycin
CLINDAMYCIN

Suspension 75mg in
5.1.7 Some other antibacterials
CHLORAMPHENICOL Capsule
250mg
Injection 1g (as sodium
COLISTIN
Injection 1 million units
SULPHOMETHATE
SODIUM

DAPTOMYCIN
Intravenous infusion
FUSIDIC ACID
Suspension 250mg in
LINEZOLID
Intravenous infusion
Suspension 100mg in
Tablet 600 mg
SODIUM FUSIDATE
Intravenous infusion
Tablet 250mg
SPECTINOMYCIN
Injection 2g
 Unlicensed  Genito Urinary Medicine TEICOPLANIN
Injection 200mg;
VANCOMYCIN
Capsule 125mg
Injection 500mg; 1g
5.1.8 Sulphonamides and trimethoprim
CO-TRIMOXAZOLE

Intravenous infusion
Suspension 240mg in
Tablet 480mg;
Chapter 5 ~ Infections: Special Section 3 of 5
SULFADIAZINE
Injection 250mg in 1ml
Tablet 500mg
5.1.9 Antituberculous drugs
RIFABUTIN

Capsule 150mg
5.1.10 Antileprotic drugs
DAPSONE

Tablet 50 mg
 For Dermatologist use  For Genito Urinary Medicine 5.1.12 Quinolones
MOXIFLOXACIN

Tablet 400mg
NALIDIXIC ACID
Tablet 500mg
OFLOXACIN
Tablet 200mg; 400mg
5.2 Antifungal drugs
AMPHOTERICIN

Intravenous infusion
CASPOFUNGIN
Intravenous infusion
ITRACONAZOLE
Capsule 100mg
 For Haematologist use  Non Policy Antibiotic Requires Solution 50mg in 5ml
 For Haematologist use  Non Policy Antibiotic Requires TERBINAFINE
Tablet 250mg
VORICONAZOLE
Tablet 200mg
 For Haematologist use  Non Policy Antibiotic Requires 5.3 Antiviral drugs
5.3.1 HIV infection
Nucleoside reverse transcriptase inhibitors
ABACAVIR

Oral solution 100mg in
Tablet 300mg
ABACAVIR with
Tablet 300mg abacavir /
lamivudine and
zidovudine (TRIZIVIR®)
DIDANOSINE

Enteric coated capsule
EMTRICITABINE
Capsule 200mg
LAMIVUDINE
Oral solution 50mg in
Tablet 150mg
Tablet 100mg
 For Chronic Hepatitis ‘B’  Use in accordance with NICE (TA96) STAVUDINE
Capsule 30mg; 40mg
TENOFOVIR
Tablet 245mg
 For Genito Urinary Medicine  For chronic Hepatitis B DISOPROXIL
TENOFOVIR
Tablet 245mg/100mg
DISOPROXIL with
Emtricitabine
(TRUVADA®)

Chapter 5 ~ Infections: Special Section 4 of 5
ZIDOVUDINE
Capsule 100mg; 250mg
Injection 200mg in 20ml
Oral solution 50mg in
ZIDOVUDINE with
Tablet 300mg/150mg
lamivudine
(COMBIVIR®)

Protease inhibitors
ATAZANAVIR

Capsule 100mg; 150mg
DARUNAVIR
Tablet 300mg
LOPINAVIR with
ritonavir (KALETRA®)
Film coated Tablet
Oral solution
RITONAVIR
Oral solutionSF 400mg
Soft capsule 100mg
SAQUINAVIR
Tablet (Invirase®)
Non-nucleoside reverse transcriptase inhibitors
EFAVIRENZ

Capsule 200mg
Oral solutionSF 150mg
Tablet 600mg
NEVIRAPINE
Suspension 50mg in
Tablet 200mg
5.3.2 Herpesvirus infections
5.3.2.1 Herpes simplex and varicella-zoster infection
FAMCICLOVIR

Tablet 250mg
 For Ophthalmologist use  For Genito Urinary Medicine 5.3.2.2 Cytomegalovirus
FOSCARNET SODIUM Intravenous infusion

GANCICLOVIR
Intravenous infusion
VALGANCYCLOVIR
Tablet 450mg
5.3.3 Viral hepatitis
5.3.3.1 Chronic Hepatitis B
ENTECAVIR

Tablet 500mcg, 1mg
Oral Solution 50mcg/ml
ADEFOVIR DIPIVOXIL Tablet 10mg
5.3.3.2 Chronic Hepatitis C
TELAPREVIR

Tablet 375mg
BOCEPREVIR
Capsule 200mg
Chapter 5 ~ Infections: Special Section 5 of 5 5.3.4 Influenza
OSELTAMIVIR

Capsule 30mg, 45mg,
Oral Suspension 60mg
in 5ml
ZANAMIVIR
Powder for inhalation
5.3.5 Respiratory syncytial virus
PALIVIZUMAB

Injection 50mg; 100mg
RIBAVIRIN
Tablet 200mg
 For Chronic Hepatitis ‘C’  Use in accordance with NICE (TA200) 5.4 Antiprotozoal drugs
5.4.1 Antimalarials
CHLOROQUINE

Tablet 250mg (=155mg
PHOSPHATE
(AVLOCHLOR®)
CHLOROQUINE

Syrup 68mg (= 50mg
SULPHATE
Tablet 200mg (= 150mg
MEFLOQUINE
Tablet 250mg
PRIMAQUINE
Tablet 7.5mg
 Treatment of Malaria  For Genito Urinary Medicine  Unlicensed Medicine PROGUANIL
Tablet 100mg
PROGUANIL
Tablet 100mg/250mg
HYDROCHLORIDE
with atovaquone
(MALARONE®)
PYRIMETHAMINE

Tablet 25mg
PYRIMETHAMINE
Tablet 25mg/500mg
with sulfadoxine
(FANSIDAR®)
QUININE

Injection 300mg in 1ml,
DIHYDROCHLORIDE
5.4.8 Drugs for pneumocystis pneumonia
PENTAMIDINE

Injection 300mg
 Unlicensed Medicine  For Genito Urinary Medicine ISETIONATE

Nebuliser solution
5.5 Anthelmintics
5.5.5 Schistosomicides
PRAZIQUANTEL

Tablet 500mg
5.5.8 Drugs for stronyloidiasis
ALBENDAZOLE

Tablet 400mg
IVERMECTIN
Tablet 3mg; 6mg

Source: http://www.thh.nhs.uk/documents/_Departments/Formulary/Chapter05_Special.pdf

sheba.co.il

Stiff-Person Syndrome Following West Nile Fever Sharon Hassin-Baer, MD; Eilon D. Kirson, MD, PhD; Lester Shulman, PhD; Aron S. Buchman, MD; Hanna Bin, PhD;Musa Hindiyeh, PhD; Lea Markevich; Ella Mendelson, PhD Background: Stiff-person syndrome is a rare autoim- Result: The search revealed a stretch of 12 amino acids mune disorder associated with antibodies against glu-in the NS1 protei

Literaturverzeichnis

Literaturverzeichnis Prevalence, Demographics and Risk Factors for Colic. AAEP Proceedings, Focus Equine Colic, Québec City, Canada http://www.pferd-aktuel .de/Wir-ueber-uns/Zahlen-Fakten 3. Tinker MK, White NA, Lessard P, Thatcher CD, Pelzer KD, Davis B, Carmel DK (1997): Prospective study of equine colic risk factors. Risk factors associated with development of diarrhea in horses after

Copyright © 2018 Medical Abstracts